Steven Jacobson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8678047/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature, 1990, 348, 245-248.	27.8	634
2	Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Medicine, 1997, 3, 1394-1397.	30.7	411
3	Classification of HHV-6A and HHV-6B as distinct viruses. Archives of Virology, 2014, 159, 863-870.	2.1	292
4	Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature, 1988, 331, 540-543.	27.8	283
5	Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1–associated myelopathy (HAM/TSP). Blood, 2002, 99, 88-94.	1.4	252
6	Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage, 2010, 49, 2924-2932.	4.2	237
7	Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. Journal of Clinical Investigation, 2016, 126, 2597-2609.	8.2	212
8	Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Annals of Neurology, 1995, 37, 167-175.	5.3	174
9	Tissue Distribution and Variant Characterization of Human Herpesvirus (HHV)–6: Increased Prevalence of HHVâ€6A in Patients with Multiple Sclerosis. Journal of Infectious Diseases, 2000, 182, 1321-1325.	4.0	157
10	Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Annals of Neurology, 1993, 33, 392-396.	5.3	142
11	CD8+ T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood, 2001, 98, 1858-1861.	1.4	141
12	Exosomes in Viral Disease. Neurotherapeutics, 2016, 13, 535-546.	4.4	141
13	Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-l–associated neuroimmunological disease. Journal of Clinical Investigation, 2005, 115, 1361-1368.	8.2	135
14	Human herpesvirus-6 entry into the central nervous system through the olfactory pathway. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13734-13739.	7.1	134
15	Immunopathogenesis of Human T Cell Lymphotropic Virus Type l–Associated Neurologic Disease. Journal of Infectious Diseases, 2002, 186, S187-S192.	4.0	133
16	Immunological findings in neurological diseases associated with antibodies to HTLV-I: Activated lymphocytes in tropical spastic paraparesis. Annals of Neurology, 1988, 23, S196-S200.	5.3	128
17	Increased Activated Human T Cell Lymphotropic Virus Type I (HTLVâ€I) Tax11â€19–Specific Memory and Effector CD8+Cells in Patients with HTLVâ€I–Associated Myelopathy/Tropical Spastic Paraparesis: Correlation with HTLVâ€I Provirus Load. Journal of Infectious Diseases, 2001, 183, 197-205.	4.0	128
18	Increased HTLVâ€I proviral load and preferential expansion of HTLVâ€I taxâ€specific CD8 ⁺ T cells in cerebrospinal fluid from patients with HAM/TSP. Annals of Neurology, 2001, 50, 807-812.	5.3	127

#	Article	IF	CITATIONS
19	High Frequency of Human Herpesvirus 6 DNA in Multiple Sclerosis Plaques Isolated by Laser Microdissection. Journal of Infectious Diseases, 2003, 187, 1377-1387.	4.0	127
20	Association of Human Herpesvirus-6B with Mesial Temporal Lobe Epilepsy. PLoS Medicine, 2007, 4, e180.	8.4	123
21	Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Annals of Neurology, 2000, 47, 306-313.	5.3	118
22	Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, 2017, 137, 41-48.	4.1	116
23	Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs. Blood, 2011, 117, 4855-4859.	1.4	112
24	Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. Journal of NeuroVirology, 2014, 20, 341-351.	2.1	111
25	Human herpes virus 6B: A possible role in epilepsy?. Epilepsia, 2008, 49, 1828-1837.	5.1	105
26	Human T cell leukemia virus type I and neurologic disease: Events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. Journal of Cellular Physiology, 2002, 190, 133-159.	4.1	104
27	Abnormally High Levels of Virus-Infected IFN-γ+CCR4+CD4+CD25+ T Cells in a Retrovirus-Associated Neuroinflammatory Disorder. PLoS ONE, 2009, 4, e6517.	2.5	104
28	Detection of Active Human Herpesvirus–6 Infection in the Brain: Correlation with Polymerase Chain Reaction Detection in Cerebrospinal Fluid. Journal of Infectious Diseases, 2007, 195, 450-454.	4.0	103
29	Evidence linking HHV-6 with multiple sclerosis: an update. Current Opinion in Virology, 2014, 9, 127-133.	5.4	102
30	HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. Journal of Clinical Investigation, 2014, 124, 3431-3442.	8.2	100
31	HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease. Annals of Neurology, 1992, 32, 651-657.	5.3	98
32	Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2011, 6, 354-361.	4.1	98
33	Inflammatory manifestations of HTLV-1 and their therapeutic options. Expert Review of Clinical Immunology, 2014, 10, 1531-1546.	3.0	98
34	Increased Expression of Human T Lymphocyte Virus Type I (HTLV-I) Tax11-19 Peptide–Human Histocompatibility Leukocyte Antigen A*201 Complexes on CD4+ CD25+T Cells Detected by Peptide-specific, Major Histocompatibility Complex–restricted Antibodies in Patients with HTLV-I–associated Neurologic Disease. Journal of Experimental Medicine, 2004, 199, 1367-1377.	8.5	97
35	Detection of human herpesvirusâ€6 in cerebrospinal fluid of patients with encephalitis. Annals of Neurology, 2009, 65, 257-267.	5.3	95
36	Review part 2: Human herpesvirusâ€6 in central nervous system diseases. Journal of Medical Virology, 2010, 82, 1669-1678.	5.0	95

#	Article	IF	CITATIONS
37	Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. Journal of NeuroVirology, 2005, 11, 384-394.	2.1	93
38	CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. PLoS Neglected Tropical Diseases, 2013, 7, e2479.	3.0	91
39	The formation of inflammatory demyelinated lesions in cerebral white matter. Annals of Neurology, 2014, 76, 594-608.	5.3	89
40	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Annals of Neurology, 2020, 88, 1034-1042.	5.3	89
41	Human Herpesvirus 6 Detection in Alzheimer's Disease Cases and Controls across Multiple Cohorts. Neuron, 2020, 105, 1027-1035.e2.	8.1	87
42	HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): A chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system. Journal of NeuroVirology, 1997, 3, 126-138.	2.1	85
43	Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology, 2017, 88, 1439-1444.	1.1	85
44	HTLV-I specific IFN-γ+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals. Journal of Neuroimmunology, 2000, 102, 208-215.	2.3	79
45	Gene Expression Profile of Herpesvirus-Infected T Cells Obtained Using Immunomicroarrays: Induction of Proinflammatory Mechanisms. Journal of Virology, 2001, 75, 11641-11650.	3.4	78
46	Immunologic Analysis of a Spinal Cord–Biopsy Specimen from a Patient with Human T-Cell Lymphotropic Virus Type I–Associated Neurologic Disease. New England Journal of Medicine, 1997, 336, 839-845.	27.0	75
47	Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain, 2013, 136, 2876-2887.	7.6	75
48	Foxp3 Represses Retroviral Transcription by Targeting Both NF-κB and CREB Pathways. PLoS Pathogens, 2006, 2, e33.	4.7	72
49	Neuronal molecular mimicry in immuneâ€mediated neurologic disease. Annals of Neurology, 1998, 44, 87-98.	5.3	70
50	Reduction in HTLVâ€I proviral load and spontaneous lymphoproliferation in HTLVâ€I–associated myelopathy/tropical spastic paraparesis patients treated with humanized antiâ€tac. Annals of Neurology, 1998, 44, 942-947.	5.3	70
51	In vivo quantification of T2⎠anisotropy in white matter fibers in marmoset monkeys. Neurolmage, 2012, 59, 979-985.	4.2	70
52	Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression. Journal of NeuroVirology, 2002, 8, 250-256.	2.1	69
53	Interferon-?1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Annals of Neurology, 2005, 57, 526-534.	5.3	68
54	Reduced Foxp3 Protein Expression Is Associated with Inflammatory Disease during Human T Lymphotropic Virus Type 1 Infection. Journal of Infectious Diseases, 2006, 193, 1557-1566.	4.0	68

#	Article	IF	CITATIONS
55	CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood, 2011, 117, 1938-1946.	1.4	67
56	In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotropic virus type I–associated neurologic disease: predominant expansion of CD8+ T cells. Blood, 2001, 98, 1506-1511.	1.4	66
57	Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide–HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nature Medicine, 2003, 9, 469-475.	30.7	62
58	HTLV-1 propels untransformed CD4+ lymphocytes into the cell cycle while protecting CD8+ cells from death. Journal of Clinical Investigation, 2006, 116, 974-983.	8.2	61
59	Neuroimmunity of HTLV-I Infection. Journal of NeuroImmune Pharmacology, 2010, 5, 310-325.	4.1	60
60	Neuroaxonal dystrophy in HTLV-1-associated myelopathy/tropical spastic paraparesis: neuropathologic and neuroimmunologic correlations. Acta Neuropathologica, 1993, 86, 224-235.	7.7	58
61	Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Annals of Neurology, 2001, 50, 486-493.	5.3	58
62	Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy. Neurologic Clinics, 2008, 26, 781-797.	1.8	58
63	Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP. Frontiers in Microbiology, 2017, 8, 2563.	3.5	57
64	Coinfection of Human Herpesviruses 6A (HHV-6A) and HHV-6B as Demonstrated by Novel Digital Droplet PCR Assay. PLoS ONE, 2014, 9, e92328.	2.5	56
65	Increased HTLV Type 1 Tax Specific CD8+Cells in HTLV Type 1-Asociated Myelopathy/Tropical Spastic Paraparesis: Correlation with HTLV Type 1 Proviral Load. AIDS Research and Human Retroviruses, 2000, 16, 1705-1709.	1.1	53
66	Multistability in a Model for CTL Response to HTLV-I Infection and Its Implications to HAM/TSP Development and Prevention. Bulletin of Mathematical Biology, 2010, 72, 681-696.	1.9	53
67	Viruses and Multiple Sclerosis. Viral Immunology, 2000, 13, 255-267.	1.3	52
68	Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients. PLoS ONE, 2008, 3, e2028.	2.5	51
69	Human T-Lymphotropic Virus Type 1 (HTLV-1) and Regulatory T Cells in HTLV-1-Associated Neuroinflammatory Disease. Viruses, 2011, 3, 1532-1548.	3.3	51
70	Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. Brain, 2018, 141, 1637-1649.	7.6	49
71	GLUT1 Is Not the Primary Binding Receptor but Is Associated with Cell-to-Cell Transmission of Human T-Cell Leukemia Virus Type 1. Journal of Virology, 2007, 81, 1506-1510.	3.4	47
72	Novel Marmoset (Callithrix jacchus) Model of Human Herpesvirus 6A and 6B Infections: Immunologic, Virologic and Radiologic Characterization. PLoS Pathogens, 2013, 9, e1003138.	4.7	47

#	Article	IF	CITATIONS
73	Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. Journal of NeuroVirology, 2005, 11, 525-534.	2.1	46
74	Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans. Journal of Virology, 2016, 90, 2195-2207.	3.4	46
75	Potential role of iron in repair of inflammatory demyelinating lesions. Journal of Clinical Investigation, 2019, 129, 4365-4376.	8.2	45
76	Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica. Blood, 2012, 119, 2829-2836.	1.4	42
77	Dysregulation of TGF-Î ² signaling and regulatory and effector T-cell function in virus-induced neuroinflammatory disease. Blood, 2008, 111, 5601-5609.	1.4	41
78	Herpesvirus trigger accelerates neuroinflammation in a nonhuman primate model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11292-11297.	7.1	40
79	SPONTANEOUS LYMPHOCYTE PROLIFERATION IN SYMPTOM-FREE HTLV-I POSITIVE JAMAICANS. Lancet, The, 1989, 334, 923-924.	13.7	39
80	Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient. Journal of NeuroVirology, 2002, 8, 53-57.	2.1	38
81	Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus). Journal of General Virology, 2006, 87, 1331-1337.	2.9	38
82	Human Herpesvirus 6 (HHV-6) Induces Dysregulation of Glutamate Uptake and Transporter Expression in Astrocytes. Journal of NeuroImmune Pharmacology, 2008, 3, 105-116.	4.1	38
83	Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals. Retrovirology, 2013, 10, 19.	2.0	38
84	Viral antigens detectable in CSF exosomes from patients with retrovirus associated neurologic disease: functional role of exosomes. Clinical and Translational Medicine, 2018, 7, 24.	4.0	38
85	Comprehensive Analysis of TCR-β Repertoire in Patients with Neurological Immune-mediated Disorders. Scientific Reports, 2019, 9, 344.	3.3	38
86	Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infectious Agents and Cancer, 2016, 11, 32.	2.6	37
87	Co-dependence of HTLV-1 p12 and p8 Functions in Virus Persistence. PLoS Pathogens, 2014, 10, e1004454.	4.7	36
88	Immunopathogenesis of human T cell lymphotropic virus type I-associated myelopathy. Current Opinion in Neurology, 2001, 14, 381-386.	3.6	35
89	Neuroimmunology of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis. Frontiers in Microbiology, 2019, 10, 885.	3.5	35
90	In vivo imaging of spinal cord atrophy in neuroinflammatory diseases. Annals of Neurology, 2014, 76, 370-378.	5.3	34

6

#	Article	IF	CITATIONS
91	Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation. Clinical Microbiology Reviews, 2020, 34, .	13.6	34
92	Cellular Immune Responses to HTLV-I: Immunopathogenic Role in HTLV-I-Associated Neurologic Disease. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, S100-S106.	0.3	34
93	Retrovirally induced CTL degranulation mediated by IL-15 expression and infection of mononuclear phagocytes in patients with HTLV-l–associated neurologic disease. Blood, 2008, 112, 2400-2410.	1.4	33
94	Translocator Protein 18ÂkDa (TSPO) Expression in Multiple Sclerosis Patients. Journal of NeuroImmune Pharmacology, 2013, 8, 51-57.	4.1	31
95	Intrathecal Tâ€cell clonal expansions in patients with multiple sclerosis. Annals of Clinical and Translational Neurology, 2016, 3, 422-433.	3.7	31
96	Imaging spinal cord atrophy in progressive myelopathies: HTLVâ€lâ€associated neurological disease (HAM/TSP) and multiple sclerosis (MS). Annals of Neurology, 2017, 82, 719-728.	5.3	30
97	High Expression of CD244 and SAP Regulated CD8+ T Cell Responses of Patients with HTLV-I Associated Neurologic Disease. PLoS Pathogens, 2009, 5, e1000682.	4.7	29
98	Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases. PLoS Pathogens, 2018, 14, e1007042.	4.7	29
99	Impaired human leukocyte antigen-restricted measles virus-specific cytotoxic T-cell response in subacute sclerosing panencephalitis. Annals of Neurology, 1989, 25, 272-280.	5.3	28
100	Cytokine Therapies in Neurological Disease. Neurotherapeutics, 2016, 13, 555-561.	4.4	27
101	Detection of HHV-6 and EBV and Cytokine Levels in Saliva From Children With Seizures: Results of a Multi-Center Cross-Sectional Study. Frontiers in Neurology, 2018, 9, 834.	2.4	27
102	Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion. Viruses, 2019, 11, 410.	3.3	27
103	Perivenular brain lesions in a primate multiple sclerosis model at 7-tesla magnetic resonance imaging. Multiple Sclerosis Journal, 2014, 20, 64-71.	3.0	25
104	Extensive Latent Retroviral Infection in Bone Marrow of Patients With HTLV-I–Associated Neurologic Disease. Blood, 1997, 89, 346-347.	1.4	24
105	Differential HHV-6A gene expression in T cells and primary human astrocytes based on multi-virus array analysis. Glia, 2006, 53, 789-798.	4.9	24
106	Custom fit 3D-printed brain holders for comparison of histology with MRI in marmosets. Journal of Neuroscience Methods, 2016, 257, 55-63.	2.5	24
107	Viral Triggers and Inflammatory Mechanisms in Pediatric Epilepsy. Molecular Neurobiology, 2019, 56, 1897-1907.	4.0	24
108	BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurology, The, 2021, 20, 639-652.	10.2	24

#	Article	IF	CITATIONS
109	Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes: the Journal of the IHMF, 2005, 12, 4-9.	0.3	24
110	Association of Human Herpesvirus-6 and Multiple Sclerosis: Here we Go Again?: Guest Editorial. Journal of NeuroVirology, 1998, 4, 471-473.	2.1	23
111	Efficacy of antiviral compounds in human herpesvirus-6–infected glial cells. Journal of NeuroVirology, 2006, 12, 284-293.	2.1	23
112	Epigenetic Modification of the FoxP3 TSDR in HAM/TSP Decreases the Functional Suppression of Tregs. Journal of NeuroImmune Pharmacology, 2014, 9, 522-532.	4.1	23
113	Utilizing 3D Printing Technology to Merge MRI with Histology: A Protocol for Brain Sectioning. Journal of Visualized Experiments, 2016, , .	0.3	23
114	Infection with HHV-6 and its role in epilepsy. Epilepsy Research, 2019, 153, 34-39.	1.6	23
115	Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology, 2019, 16, 35.	2.0	23
116	Viruses in chronic progressive neurologic disease. Multiple Sclerosis Journal, 2018, 24, 48-52.	3.0	22
117	Immunopathogensis of HTLV-I associated neurologic disease: molecular, histopathologic, and immunologic approaches. Frontiers in Bioscience - Landmark, 2004, 9, 2527.	3.0	21
118	CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. Glia, 2005, 52, 252-258.	4.9	21
119	Mechanism of Neuroinflammation: Enhanced Cytotoxicity and IL-17 Production via CD46 Binding. Journal of NeuroImmune Pharmacology, 2010, 5, 469-478.	4.1	20
120	Targeting the Binding Interface on a Shared Receptor Subunit of a Cytokine Family Enables the Inhibition of Multiple Member Cytokines with Selectable Target Spectrum. Journal of Biological Chemistry, 2015, 290, 22338-22351.	3.4	20
121	The "central vein sign―in inflammatory demyelination: The role of fibrillar collagen type I. Annals of Neurology, 2019, 85, 934-942.	5.3	20
122	Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease. Retrovirology, 2012, 9, 16.	2.0	19
123	Human Herpesvirus 6 as a Viral Trigger in Mesial Temporal Lobe Epilepsy. Journal of Infectious Diseases, 2015, 212, 1011-1013.	4.0	19
124	Natural History of Viral Markers in Children Infected with Human T Lymphotropic Virus Type I in Jamaica. Journal of Infectious Diseases, 2006, 194, 552-560.	4.0	18
125	Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder. Journal of Clinical Investigation, 2020, 130, 5551-5561.	8.2	18
126	Demonstration of human T-cell lymphotrophic virus type I (HTLV-I) from an HTLV-I seronegative South Indian patient with chronic, progessive spastic paraparesis. Annals of Neurology, 1993, 34, 867-870.	5.3	17

#	Article	IF	CITATIONS
127	Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-l–associated neurologic disease. Blood, 2011, 117, 3363-3369.	1.4	17
128	In vivo immunogenicity of Tax(11–19) epitope in HLA-A2/DTR transgenic mice: Implication for dendritic cell-based anti-HTLV-1 vaccine. Vaccine, 2014, 32, 3274-3284.	3.8	16
129	Common Î ³ -chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11030-11035.	7.1	16
130	Vaccinations for Neuroinfectious Disease: A Global Health Priority. Neurotherapeutics, 2016, 13, 562-570.	4.4	16
131	An Altered Peptide Ligand Antagonizes Antigen-Specific T Cells of Patients with Human T Lymphotropic Virus Type I-Associated Neurological Disease. Journal of Immunology, 2000, 164, 5192-5198.	0.8	15
132	Use of a multi-virus array for the study of human viral and retroviral pathogens: gene expression studies and ChIP-chip analysis. Retrovirology, 2004, 1, 10.	2.0	15
133	Complete replication cycle and acquisition of tegument in nucleus of human herpesvirus 6A in astrocytes and in T-cells. Journal of Medical Virology, 2006, 78, 1542-1553.	5.0	15
134	Utility of HTLV proviral load quantification in diagnosis of HTLV-1-associated myelopathy requires international standardization. Journal of Clinical Virology, 2013, 58, 584-586.	3.1	15
135	Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P). Viruses, 2022, 14, 136.	3.3	15
136	Limited T cell receptor usage by HTLV-I tax-specific, HLA class I restricted cytotoxic T lymphocytes from patients with HTLV-I associated neurological disease. Journal of Neuroimmunology, 1995, 63, 47-53.	2.3	14
137	HTLV-1 Infection and Neuropathogenesis in the Context of Rag1-/-γc-/- (RAG1-Hu) and BLT Mice. Journal of NeuroImmune Pharmacology, 2017, 12, 504-520.	4.1	14
138	Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability. Neurolmage: Clinical, 2021, 30, 102680.	2.7	13
139	Development of neurologic diseases in a patient with primate T lymphotropic virus type 1 (PTLV-1). Retrovirology, 2016, 13, 56.	2.0	12
140	Analyses of HTLV-1 sequences suggest interaction between ORF-I mutations and HAM/TSP outcome. Infection, Genetics and Evolution, 2016, 45, 420-425.	2.3	12
141	Role of Exosomes in Human Retroviral Mediated Disorders. Journal of NeuroImmune Pharmacology, 2018, 13, 279-291.	4.1	12
142	Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls. Multiple Sclerosis Journal, 2019, 25, 644-652.	3.0	12
143	HTLVâ€lâ€Associated Myelopathy/Tropical Spastic Paraparesis: Semiautomatic Quantification of Spinal Cord Atrophy from 3â€Dimensional MR Images. Journal of Neuroimaging, 2014, 24, 74-78.	2.0	11
144	An evaluation of HHV-6 as an etiologic agent in Hodgkin lymphoma and brain cancer using IARC criteria for oncogenicity. Infectious Agents and Cancer, 2019, 14, 31.	2.6	11

#	Article	IF	CITATIONS
145	Clinical trial of a humanized antiâ€ILâ€2/ILâ€15 receptor β chain in HAM/TSP. Annals of Clinical and Translational Neurology, 2019, 6, 1383-1394.	3.7	9
146	Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis. Journal of NeuroVirology, 2020, 26, 652-663.	2.1	9
147	Impaired Measles-Specific Cytotoxic T-Cell Response in Subacute Sclerosing Panencephalitis. Annals of the New York Academy of Sciences, 1988, 540, 645-648.	3.8	8
148	Reply to "HHV-6 and multiple sclerosis― Nature Medicine, 1998, 4, 538-538.	30.7	8
149	Role of Viral Infection in the Aetiology of Multiple Sclerosis. CNS Drugs, 1999, 12, 1-7.	5.9	8
150	Localization of retrovirus in the central nervous system of a patient co-infected with HTLV-1 and HIV with HAM/TSP and HIV-associated dementia. Journal of NeuroVirology, 2001, 7, 61-65.	2.1	8
151	The spectrum of spinal cord lesions in a primate model of multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 284-293.	3.0	8
152	Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Annals of Neurology, 2000, 47, 306-313.	5.3	8
153	Hypoxanthine-Guanine Phosphoribosyltransferase Reporter Gene Mutation for Analysis ofin VivoClonal Amplification in Patients with HTLV Type 1-Associated Myelopathy/Tropical Spastic Paraparesis. AIDS Research and Human Retroviruses, 2000, 16, 1747-1752.	1.1	7
154	Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT–lipid–PFA on human herpesvirus-6B infected cells. Journal of Clinical Virology, 2009, 46, 10-14.	3.1	7
155	Ultrahigh-resolution MRI Reveals Extensive Cortical Demyelination in a Nonhuman Primate Model of Multiple Sclerosis. Cerebral Cortex, 2021, 31, 439-447.	2.9	7
156	Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP. Annals of Clinical and Translational Neurology, 2021, 8, 1970-1985.	3.7	7
157	Virus-Specific Cytotoxic T Cells in Multiple Sclerosis. Annals of the New York Academy of Sciences, 1988, 532, 273-279.	3.8	6
158	Natalizumab and Immune Cells. Archives of Neurology, 2006, 63, 1366.	4.5	6
159	Using Droplet Digital PCR to Detect Coinfection of Human Herpesviruses 6A and 6B (HHV-6A and) Tj ETQq1 1 0.	.784314 rş 0.9	gBT ₆ /Overlo
160	HHVâ€6 and hippocampal volume in patients with mesial temporal sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1674-1680.	3.7	6
161	Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy. Viruses, 2022, 14, 1246.	3.3	6
162	Detection of HHV-6B in post-mortem central nervous system tissue of a post-bone marrow transplant recipient: a multi-virus array analysis. Journal of Clinical Virology, 2006, 37, S57-S62.	3.1	5

#	Article	IF	CITATIONS
163	Human herpesvirus 6 and epilepsy. Epilepsia Open, 2021, 6, 777-780.	2.4	5
164	HPRT mutations, TCR gene rearrangements, and HTLV-1 integration sites define in vivo T-cell clonal lineages. Environmental and Molecular Mutagenesis, 2005, 45, 326-337.	2.2	4
165	HHV-6 and the Central Nervous System. Perspectives in Medical Virology, 2006, 12, 213-223.	0.1	4
166	Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis. , 2016, , 175-220.		4
167	Progressive multifocal leukoencephalopathy lesion and brain parenchymal segmentation from MRI using serial deep convolutional neural networks. NeuroImage: Clinical, 2020, 28, 102499.	2.7	4
168	Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet Journal of Rare Diseases, 2020, 15, 175.	2.7	4
169	Effect of Teriflunomide on Cells From Patients With Human T-cell Lymphotropic Virus Type 1–Associated Neurologic Disease. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	4
170	Viruses and Multiple Sclerosis. , 0, , 99-124.		4
171	Immune Response to HTLV-I and HTLV-II. , 0, , 159-190.		4
172	Parkinsonism in the course of HTLV-I-associated myelopathy. Movement Disorders, 2005, 20, 613-615.	3.9	3
173	Viral Infections of the Central Nervous System: Pathogenesis to Therapeutics. Journal of NeuroImmune Pharmacology, 2010, 5, 267-270.	4.1	3
174	Dynamic acquisition of HTLV-1 tax protein by mononuclear phagocytes: Role in neurologic disease. Journal of Neuroimmunology, 2017, 304, 43-50.	2.3	3
175	Differential activation of neuroinflammatory pathways in children with seizures: A cross-sectional study. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 150-158.	2.0	3
176	International Retrovirology Association brings together scientists and clinicians to bridge discoveries about human T-lymphotropic viruses from the laboratory to clinical trials. Retrovirology, 2005, 2, 22.	2.0	2
177	Opinion and Special Articles: Cerebellar ataxia and liver failure complicating IPEX syndrome. Neurology, 2020, 96, 10.1212/WNL.000000000011195.	1.1	2
178	Infection and Multiple Sclerosis. , 2004, , 559-582.		2
179	Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study. Multiple Sclerosis Journal, 2022, 28, 1891-1902.	3.0	2
180	Atypical human T-cell lymphotropic virus type-I-associated T-cell lymphoma in a low-prevalence alaska native population. Implications for Disease Surveillance. Cancer, 1993, 71, 4072-4076.	4.1	1

#	Article	IF	CITATIONS
181	Detection of HTLV-I in peripheral blood lymphocytes from patients with chronic HTLV-I-associated myelopathy/tropical spastic paraparesis and asymptomatic carriers by PCR-in situ hybridization. Journal of Biomedical Science, 1997, 4, 54-60.	7.0	1
182	Immunopathogenic CSF TCR repertoire signatures in virus-associated neurologic disease. JCI Insight, 2021, 6, .	5.0	1
183	Reviews in NeuroVirology: An introduction. Journal of NeuroVirology, 2005, 11, 411-411.	2.1	0
184	Viral Infection and Multiple Sclerosis. , 2007, , 188-213.		0
185	Human T-Cell Lymphotropic Virus Type 1 Infection. , 2013, , 183-207.		Ο
186	HHV-6 and Multiple Sclerosis. , 2014, , 123-142.		0
187	Human T-Cell Lymphotropic Virus Types 1 and 2. , 2016, , 674-681.		0
188	Neuroimmunomodulation of Human T-Lymphotrophic Virus Type I/II Infection. , 2017, , 421-436.		0
189	Reply to Zahednasab et al.: HHV-6 and marmoset EAE. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12127-E12127.	7.1	0
190	Peptide/HLA-GFP Complexes. , 2005, , 261-274.		0
191	HTLV-1 Infected CD4+CD25+CCR4+ T-Cells Disregulate Balance of Inflammation and Tolerance in HTLV-1 Associated Neuroinflammatory Disease 2011 189-198		0